Full Text View
Tabular View
No Study Results Posted
Related Studies
Mechanisms of Endothelial Cell Dysfunction in Sleep Apnea
This study is not yet open for participant recruitment.
Verified by Weill Medical College of Cornell University, March 2009
First Received: March 10, 2009   No Changes Posted
Sponsors and Collaborators: Weill Medical College of Cornell University
National Institutes of Health (NIH)
Information provided by: Weill Medical College of Cornell University
ClinicalTrials.gov Identifier: NCT00859950
  Purpose

Sleep apnea is a common sleep disorder characterized by temporary stops in breathing during sleep and has been associated with the development of cardiovascular disease. This research will investigate one potential mechanism leading to the development of cardiovascular disorder, specifically, the blockage of blood vessels called "vascular occlusion", in subjects with sleep apnea. A group of healthy controls will be used for comparison.

All subjects will undergo clinical evaluation followed by an overnight sleep study and a morning blood draw. Subjects with sleep apnea will be treated according to standard clinical management and followed under the research protocol for one month. At the end of one month, a repeat blood draw will be performed on the sleep apnea subjects for comparative analysis. If a control subject is found to have any abnormality during this research study, he or she will be referred for further clinical evaluation.


Condition Intervention
Obstructive Sleep Apnea
Intermittent Hypoxemia
 Device: Continuous Positive Airway Pressure (CPAP)

MedlinePlus related topics: Sleep Apnea
U.S. FDA Resources
Study Type: Interventional
Study Design: Basic Science, Non-Randomized, Open Label, Parallel Assignment
Official Title: Mechanisms of Endothelial Cell Dysfunction in Sleep Apnea

Further study details as provided by Weill Medical College of Cornell University:

Primary Outcome Measures:
  • NTPDase (vascular enzyme) activity in white blood cells [ Time Frame: Day 1 (all subjects) and Day 34 (post treatment - sleep apnea only) ] [ Designated as safety issue: No ]
  • Circulating endothelial cells (CECs) [ Time Frame: Day 1 (all subjects) and Day 34 (post treatment - sleep apnea only) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Determine the effect of sleep apnea therapy in increasing vascular enzyme (NTPDase) activity and decreasing the level of circulating endothelial cells (CECs). [ Time Frame: At completion of study ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: April 2009
Estimated Study Completion Date: October 2013
Estimated Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Sleep Apnea: Active Comparator
Subjects found to have Obstructive Sleep Apnea (OSA) with Intermittent Hypoxemia (IH). This arm will undergo a pre-treatment blood draw, one month of Continuous Positive Airway Pressure (CPAP) to treat OSA, and a post-treatment blood draw.
Device: Continuous Positive Airway Pressure (CPAP)
Continuous positive airway pressure (CPAP) is a method of respiratory ventilation which is accepted as the gold standard to treat Obstructive Sleep Apnea (OSA). Subjects found to have OSA after the Nocturnal Polysomnography (NPSG) will be trained in the use of CPAP and will be instructed to use CPAP every night for 30 nights. These subjects will then return for a post-treatment blood draw.
Normal Control: No Intervention
Subject found to have no evidence of Obstructive Sleep Apnea (OSA) after Nocturnal Polysomnography (NPSG). These subjects will only undergo a blood draw and will not have the Continuous Positive Airway Pressure (CPAP) treatment.

Detailed Description:

The importance of this project is to investigate mechanisms of vascular disease in sleep apnea and determine pathways for intervention, aiming to prevent the development of cardiovascular disease in these individuals.

This proposed research aims to evaluate both NTPDase activity in lymphocytes and levels of circulating endothelial cells (CECs) in patients with intermittent hypoxemia (IH) due to obstructive sleep apnea (OSA) and healthy controls. This is an original approach to define mechanisms which underlie the high incidence of occlusive vascular events in patients with OSA. The evaluation of such pathophysiological mechanisms will lead to a better understanding of the pathways involved and the development of therapeutic strategies targeting the reduction or avoidance of endothelial injury with the ultimate goal of reducing morbidity and mortality associated with these pathologic events in sleep apnea. The standard of care will be used in this protocol, which involves the use of CPAP (continuous positive airway pressure) for treating sleep apnea.

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Study Group 1: Sleep Apnea

Inclusion Criteria:

  • 21 years or older
  • Presence of intermittent hypoxemia (IH) and obstructive sleep apnea (OSA)
  • No diagnosis of hypertension, coronary artery disease, diabetes, stroke, or evidence of underlying vascular disease

Exclusion Criteria:

  • Smoking
  • Pregnancy
  • Known cardiovascular disease, stroke, or diabetes
  • Current or previous treatment for sleep apnea
  • Central or Cheyne-Stokes sleep apnea
  • Use of supplemental oxygen at night
  • Alcohol abuse
  • Regular use of sedatives
  • Regular use of aspirin or cholesterol lowering agents

Study Group 2: Normal Controls

Inclusion Criteria:

  • 21 years or older
  • No diagnosis of intermittent hypoxemia (IH) or obstructive sleep apnea (OSA)
  • No diagnosis of hypertension, coronary artery disease, diabetes, stroke, or evidence of underlying vascular disease

Exclusion Criteria:

  • Smoking
  • Pregnancy
  • Known cardiovascular disease, stroke, or diabetes
  • Use of supplemental oxygen at night
  • Alcohol abuse
  • Regular use of sedatives
  • Regular use of aspirin or cholesterol lowering agents
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00859950

Contacts
Contact: Claire Schlemme 646-962-2672 ces2009@med.cornell.edu

Locations
United States, New York
Weill Cornell Medical College - Weill Cornell Pulmonary Associates
New York, New York, United States, 10021
Sponsors and Collaborators
Weill Medical College of Cornell University
National Institutes of Health (NIH)
Investigators
Principal Investigator: Ana C Krieger, MD, MPH Weill Cornell Medical College
  More Information

No publications provided

Responsible Party: Weill Cornell Medical College ( Ana C. Krieger, MD )
Study ID Numbers: 0811010102
Study First Received: March 10, 2009
Last Updated: March 10, 2009
ClinicalTrials.gov Identifier: NCT00859950     History of Changes
Health Authority: United States: Institutional Review Board

Keywords provided by Weill Medical College of Cornell University:
Sleep Apnea
Vascular Occlusion
Nocturnal Polysomnography
Continuous Positive Airway Pressure

Study placed in the following topic categories:
Signs and Symptoms
Sleep Apnea Syndromes
Respiratory Tract Diseases
Apnea
Respiration Disorders
 Sleep Apnea, Obstructive
Dyssomnias
Sleep Disorders
Signs and Symptoms, Respiratory
Sleep Disorders, Intrinsic

Additional relevant MeSH terms:
Signs and Symptoms
Sleep Apnea Syndromes
Respiratory Tract Diseases
Apnea
Nervous System Diseases
Respiration Disorders
 Sleep Apnea, Obstructive
Sleep Disorders
Dyssomnias
Signs and Symptoms, Respiratory
Sleep Disorders, Intrinsic

ClinicalTrials.gov processed this record on May 06, 2009



U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services